State of Alaska Department of Revenue Has $15.41 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

State of Alaska Department of Revenue trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 10.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 189,229 shares of the medical equipment provider's stock after selling 22,270 shares during the period. State of Alaska Department of Revenue owned approximately 0.08% of Hologic worth $15,413,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Wolff Wiese Magana LLC acquired a new position in Hologic during the third quarter valued at $25,000. Innealta Capital LLC acquired a new position in Hologic in the 2nd quarter worth about $25,000. iA Global Asset Management Inc. acquired a new position in Hologic in the 1st quarter worth about $37,000. Sunbelt Securities Inc. acquired a new position in Hologic in the 2nd quarter worth about $37,000. Finally, Cromwell Holdings LLC increased its position in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after purchasing an additional 416 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Hologic news, insider Brandon Schnittker sold 476 shares of the firm's stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the firm's stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brandon Schnittker sold 476 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares of the company's stock, valued at approximately $310,415.85. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company's stock.

Hologic Stock Performance

NASDAQ:HOLX traded down $0.08 during mid-day trading on Friday, hitting $80.83. 1,318,290 shares of the company's stock traded hands, compared to its average volume of 1,407,811. The firm has a 50 day moving average of $80.92 and a two-hundred day moving average of $77.86. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The firm has a market capitalization of $18.77 billion, a price-to-earnings ratio of 27.49, a price-to-earnings-growth ratio of 2.96 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the company earned $0.93 EPS. The firm's revenue for the quarter was up 2.7% compared to the same quarter last year. On average, equities analysts forecast that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on HOLX shares. Leerink Partners dropped their target price on Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. JPMorgan Chase & Co. upped their target price on Hologic from $91.00 to $95.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 30th. Citigroup lowered Hologic from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Royal Bank of Canada reiterated a "sector perform" rating and set a $82.00 price target on shares of Hologic in a research note on Friday, August 16th. Finally, StockNews.com downgraded Hologic from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Hologic presently has a consensus rating of "Moderate Buy" and a consensus price target of $87.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.